PHA Canada Welcomes Federal Government Investment to Support Access to Rare Disease Drugs
The Pulmonary Hypertension Association of Canada Welcomes Federal Government Investment to Support Access to Rare Disease Drugs
Vancouver, British Columbia (March 22, 2023) - The Pulmonary Hypertension Association of Canada (PHA Canada) is pleased to see the announcement of $1.5 billion over three years in support of a National Strategy for Drugs for Rare Diseases. Most of this funding, $1.4 billion, will go to the provinces through bilateral, individualized agreements. As a critical next step to advance the development of these bilateral agreements, the Government of Canada will engage with provinces and territories to jointly determine a small set of new and emerging drugs that would be cost-shared and covered in a consistent way across the country.
“This is a good start. PHA Canada has long advocated for PH patients to receive equitable and timely access to optimal treatment options to manage their disease,” said Nicole Dempsey, Chair of PHA Canada’s Board of Directors. “The disparities that exist in the access to treatments PH patients may receive, depending on what province or territory they live in or whether they have private insurance, can significantly impact their quality of life and health outcomes. If the optimal treatments for pulmonary hypertension are included in the list of drugs publicly covered across Canada, it will go a long way to improving the lives of many people living with PH.”
The announcement included funding for research, improved data sharing for rare diseases, and establishing a stakeholder Implementation Advisory Group that will provide advice and continued engagement as the plan is unrolled. The Advisory Group, to be struck by Summer 2023, will comprise representatives of public and private drug plans, patients and clinicians, the pharmaceutical industry, and others.
What this means for Canadians living with pulmonary hypertension needs to be clarified. PHA Canada is encouraged by the proposed approach includes a patient input mechanism. We will be working to identify opportunities to have the voices of the PH community included in the process.
Background
Health Canada press release: https://lnkd.in/gR3A_3YJ
Canadian Organization for Rare Disorders (CORD) press release: bit.ly/3FDU3Ub
About Pulmonary Hypertension
Pulmonary hypertension—or PH—is a rare and very complex lung disease, which is progressive and potentially fatal. PH is characterized by high blood pressure in the pulmonary arteries (blood vessels) that carry blood to the lungs. PH means that the blood pressure in the arteries that carry blood to the lungs is too high. This excessive pressure is usually caused by restriction or blockage in the blood vessels. PH can cause the heart to work harder and lead to heart failure.
For more information, please visit: www.phacanada.ca/What-is-PH/About-PH
About the Pulmonary Hypertension Association of Canada (PHA Canada)
PHA Canada is a federally registered charity whose mission is to empower the Canadian pulmonary hypertension community through support, education, advocacy, awareness, and research. PHA Canada was established in 2008 by patients, caregivers, and healthcare professionals to work together to better the lives of Canadians affected by pulmonary hypertension and represent a united national PH community.
For more information about the Pulmonary Hypertension Association of Canada, please visit: www.phacanada.ca
— END —
It's encouraging to see https://fremovebg.com/ highlight the $1.5 billion federal commitment, especially the plan to develop a consistent national approach to drug coverage. This bilateral agreement process with provinces feels like a crucial step to ensure access isn't determined by where someone lives. Hopefully, this momentum continues for all rare disease communities.
Really appreciate how this article highlights the importance of improving access to rare disease medications. For patients and families, timely treatment can make a meaningful difference in everyday life. The discussion also reminded me of the importance of accessible healthcare, something I value when reading about sherwaytrilliumdental.ca . Continued collaboration between governments, healthcare providers, and patient organizations remains essential.
bg remover free is a helpful resource for understanding the impact of this funding on rare disease communities. It's encouraging to see the $1.4 billion allocated to provinces for bilateral agreements. The next step of defining a consistent national list of cost-shared drugs sounds like a crucial and complex process.
This release makes clear that federal investment and bilateral agreements aim to create consistent coverage across provinces for rare disease drugs, which could profoundly affect people with pulmonary hypertension. The success of that approach depends on timely formation of the Implementation Advisory Group and explicit mechanisms for patient input, https://minimaxh3videogenerator.com/ without those details, patients and providers will struggle to understand when and how coverage improvements will reach them. Regular public updates and measurable milestones would help evaluate progress.
The statement from PHA Canada focuses on how a national, cost-shared approach to rare disease drugs could reduce province-by-province disparities in pulmonary hypertension care. While $1.5 billion is a significant start, PH patients need concrete assurances that optimal treatments will be included and uniformly accessible, BlockBlast the planned Advisory Group should include PH patients and clinicians with transparent rules for input and decision-making. Monitoring implementation and outcomes will be necessary to ensure real improvements in access and health equity.